Clinical trial · people

Retatrutide lowered ANGPTL3/8 in step with triglycerides and LDL-C

Checked against the paper Clinical trialPublished by PepVault

The takeaway

This paper points to the glucagon receptor side of retatrutide as one possible reason its blood fat and LDL cholesterol drops happen, through lower ANGPTL3/8.

Kind
Clinical trial
Studied in
People
Published
2025
Journal
Diabetes Obes Metab

What they tested

The team tested whether retatrutide lowers blood triglycerides and LDL-C partly by reducing a blood protein complex called ANGPTL3/8.

How the study was done

A post hoc analysis, meaning a look back at data after the trials ended, of two phase 2 retatrutide trials: one in people with type 2 diabetes and one in people with obesity or overweight without diabetes. The team also ran lab tests on primary human hepatocytes, liver cells taken from people, exposed to retatrutide, GIP, GLP-1, glucagon and an antibody that blocks the glucagon receptor.

A woman in glasses at a kitchen table with a laptop, a mug and her phone

Model. Individual results vary.

PepVault for iPhone

Taking retatrutide? Keep your own record

Log each dose, your weight and how you feel, in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

What they found

In people with type 2 diabetes, ANGPTL3/8 fell with the 8 and 12 mg retatrutide doses. In people with obesity or overweight without diabetes, it fell with the 1, 4, 8 and 12 mg doses. In both groups, the drop in ANGPTL3/8 tracked the drops in triglycerides (blood fats) and LDL-C (LDL cholesterol) seen with retatrutide. In lab-grown human liver cells, both glucagon and retatrutide cut ANGPTL3/8 release, and the glucagon receptor-blocking antibody stopped that effect.

What it doesn’t show

This was a post hoc look at two trials, and changes that move together do not show that one causes the other. The liver cell results come from lab work, not from people.

The paper

Wen et al. Decreases in circulating ANGPTL3/8 concentrations following retatrutide treatment parallel reductions in serum lipids. Diabetes Obes Metab. 2025.

The compound

More studies on Retatrutide

Researched and drafted with AI, then checked claim by claim against the primary sources linked below by a separate review pass. Published by PepVault. Last reviewed . Spot an error? feedback@pepvault.app. How we research. This page reports one study; it is not medical advice.

Track it in the app

PepVault for iPhone

Taking retatrutide? Keep your own record

Log each dose, your weight and how you feel, in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Explore the live demo